tbuckley/cabot-search huggingface dataset:
Blood-brain barrier dysfunction in aging induces hyperactivation of TGFβ signaling and chronic yet reversible neural dysfunction
Authors: Vladimir V. Senatorov, Aaron R. Friedman, Dan Z. Milikovsky, Jonathan Ofer, Rotem Saar-Ashkenazy, Adiel Charbash, Naznin Jahan, Gregory Chin, Eszter Mihaly, Jessica M. Lin, Harrison J. Ramsay, Ariana Moghbel, Marcela K. Preininger, Chelsy R. Eddings, Helen V. Harrison, Rishi Patel, Yishuo Shen, Hana Ghanim, Huanjie Sheng, Ronel Veksler, Peter H. Sudmant, Albert Becker, Barry Hart, Michael A. Rogawski, Andrew Dillin, Alon Friedman, Daniela Kaufer
Journal: Science Translational Medicine (2019)

Aging involves a decline in neural function that contributes to cognitive impairment and disease. However, the mechanisms underlying the transition from a young-and-healthy to aged-and-dysfunctional brain are not well understood. Here, we report breakdown of the vascular blood-brain barrier (BBB) in aging humans and rodents, which begins as early as middle age and progresses to the end of the life span. Gain-of-function and loss-of-function manipulations show that this BBB dysfunction triggers hyperactivation of transforming growth factor-β (TGFβ) signaling in astrocytes, which is necessary and sufficient to cause neural dysfunction and age-related pathology in rodents. Specifically, infusion of the serum protein albumin into the young rodent brain (mimicking BBB leakiness) induced astrocytic TGFβ signaling and an aged brain phenotype including aberrant electrocorticographic activity, vulnerability to seizures, and cognitive impairment. Furthermore, conditional genetic knockdown of astrocytic TGFβ receptors or pharmacological inhibition of TGFβ signaling reversed these symptomatic outcomes in aged mice. Last, we found that this same signaling pathway is activated in aging human subjects with BBB dysfunction. Our study identifies dysfunction in the neurovascular unit as one of the earliest triggers of neurological aging and demonstrates that the aging brain may retain considerable latent capacity, which can be revitalized by therapeutic inhibition of TGFβ signaling.
退休对主要的慢性疾病和疲劳的影响：法国职业相关队列研究（GAZEL研究）
Authors: Hugo, Westerlund, Jussi, Vahtera, Jane, Fettle, Archana, Singh-Manoux, Jaana, Pentti, Maria, Melchior, Constanze, Leineweber, Markus, Jokela, Johannes, Siegrist, Marcel, Goldberg
Journal: BMJ (2011)

目的 应用纵向分析确定退休是否会改变新发慢性疾病、抑郁症状和疲劳的危险性。 设计 对退休前后各7年进行重复评估的前瞻性研究。 地点1989年至2007年间法国大型职业相关的队列研究（GAZEI。研究）。
Outcome of Salvage Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML) Who Failed Imatinib after Developing BCR-ABL Kinase Mutation.
Authors: Elias Jabbour, Hagop Kantarjian, Moshe Talpaz, Dan Jones, Susan O’Brien, Francis Giles, Guillermo Garcia-Manero, Farhad Ravandi, Stefan Faderl, Srdan Verstovsek, Mary Beth Rios, Jorge Cortes
Journal: Blood (2005)
Endoscopic treatment of complicated bile duct stricture after surgery for traumatic bile duct injury
Authors: Valerio Pontecorvi, Lorenzo Dioscoridi, Edoardo Forti, Marcello Cintolo, Aurora Giannetti, Simone Vagnarelli, Massimiliano Mutignani
Journal: Endoscopy (2019)

Biliodigestive anastomoses are the most frequently performed surgeries [3], but the risk of long-term adverse events is high, especially for biliary anastomotic strictures [4].
Chronic inflammation in the etiology of disease across the life span
Authors: David Furman, Judith Campisi, Eric Verdin, Pedro Carrera-Bastos, Sasha Targ, Claudio Franceschi, Luigi Ferrucci, Derek W. Gilroy, Alessio Fasano, Gary W. Miller, Andrew H. Miller, Alberto Mantovani, Cornelia M. Weyand, Nir Barzilai, Jorg J. Goronzy, Thomas A. Rando, Rita B. Effros, Alejandro Lucia, Nicole Kleinstreuer, George M. Slavich
Journal: Nature Medicine (2019)
Targeting and imaging of monocyte-derived macrophages in rat's injured artery following local delivery of liposomal quantum dots
Authors: Gil Aizik, Nir Waiskopf, Majd Agbaria, Meital Ben-David-Naim, Mirjam M. Nordling-David, Doaa Jbara-Agbaria, Uri Banin, Gershon Golomb
Journal: Journal of Controlled Release (2019)
Clonal Evolution and Sub-Clonal Architecture In Paediatric T-Cell Acute Lymphoblastic Leukaemia (T-ALL)
Authors: Caroline L Furness, Marcela B Mansur, Victoria J Weston, Frederik W Van Delft, Christine J Harrison, Lyndal Kearney, Anthony M Ford, Pamela R Kearns, Frcpch Frcpch, Nicola E Potter, Jean Soulier, Adolfo A. Ferrando, Mel Greaves
Journal: Blood (2013)
A sericin/ graphene oxide composite scaffold as a biomimetic extracellular matrix for structural and functional repair of calvarial bone
Authors: Chao Qi, Yan Deng, Luming Xu, Cheng Yang, Yuanyuan Zhu, Guobin Wang, Zheng Wang, Lin Wang
Journal: Theranostics (2019)

Bone defects affect millions of people worldwide each year, leading to severe disabilities. Biomimetic scaffolds mediated tissue regeneration represents a promising alternative for bone repair. However, the major problem associated with most currently clinical available artificial bone substitutes (scaffolds) is that they mainly possess filling function but lack of osteo-induction abilities. Therefore, development of biomaterials with osteo-induction property for effective bone regeneration is highly desired. Methods: We report the design and fabrication of a photo-crosslinked sericin methacryloyl (SerMA)/ graphene oxide (GO) hydrogel (SMH/GO) as a biomimetic scaffold for the functional repair of the bone. The mechanical strength, degradation and biocompatibility behavior of SMH/GO hydrogel were measured in vitro. The effect of SMH/GO hydrogel on BMSCs proliferation, migration, osteogenesis differentiation was assessed. After that, SMH/GO-2 was used as an artificial bone substitute for bone regeneration after calvarial defects and effect on bone repair was evaluated by histological, X-Ray and microCT analysis. Furthermore, the potential mechanism of SMH/GO hydrogel regulating BMSCs migration and differentiation was investigated by RNA sequencing. Results: This scaffold has good biocompatibility, cell adhesive property, proliferation- and migration-promoting effects, and osteogenic induction property. After being implanted in a rat calvarial defect model, this SMH/GO scaffold effectively promotes new bone regeneration and achieves structural and functional repair within 12 weeks by inducing autologous bone marrow-derived mesenchymal stem cells (BMSCs) differentiation. By utilizing cell-biological assays and RNA sequencing, we reveal its possible regeneration mechanisms: the SMH/GO hydrogel regulates BMSCs migration and osteo-differentiation via activating MAPK, TNF, and chemokine signaling for bone regeneration. Conclusion: Aiming to meet clinical demands and overcome current limitations of existing artificial bones, we have developed a new type of sericin/ graphene oxide composite scaffold and provided histological, functional, and molecular evidence demonstrating that it is capable of effectively repairing defective bones by inducing autologous BMSCs directional migration and osteogenic differentiation.
Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint
Authors: Erik Voets, Marc Paradé, David Lutje Hulsik, Sanne Spijkers, Wout Janssen, Joost Rens, Inge Reinieren-Beeren, Gilbert van den Tillaart, Sander van Duijnhoven, Lilian Driessen, Maurice Habraken, Peter van Zandvoort, Joost Kreijtz, Paul Vink, Andrea van Elsas, Hans van Eenennaam
Journal: Journal for ImmunoTherapy of Cancer (2019)

<h3>Background</h3> Accumulating preclinical data indicate that targeting the SIRPα/CD47 axis alone or in combination with existing targeted therapies or immune checkpoint inhibitors enhances tumor rejection. Although several CD47-targeting agents are currently in phase I clinical trials and demonstrate activity in combination therapy, high and frequent dosing was required and safety signals (acute anemia, thrombocytopenia) were recorded frequently as adverse events. Based on the restricted expression pattern of SIRPα we hypothesized that antibodies targeting SIRPα might avoid some of the concerns noted for CD47-targeting agents. <h3>Methods</h3> SIRPα-targeting antibodies were generated and characterized for binding to human SIRPα alleles and blockade of the interaction with CD47. Functional activity was established in vitro using human macrophages or neutrophils co-cultured with human Burkitt's lymphoma cell lines. The effect of SIRPα versus CD47 targeting on human T-cell activation was studied using an allogeneic mixed lymphocyte reaction and a <i>Staphylococcus</i> enterotoxin B-induced T-cell proliferation assay. Potential safety concerns of the selected SIRPα-targeting antibody were addressed in vitro using a hemagglutination assay and a whole blood cytokine release assay, and in vivo in a single-dose toxicity study in cynomolgus monkeys. <h3>Results</h3> The humanized monoclonal IgG2 antibody ADU-1805 binds to all known human SIRPα alleles, showing minimal binding to SIRPβ1, while cross-reacting with SIRPγ, and potently blocking the interaction of SIRPα with CD47. Reduced FcγR binding proved critical to retaining its function towards phagocyte activation. In vitro characterization demonstrated that ADU-1805 promotes macrophage phagocytosis, with similar potency to anti-CD47 antibodies, and enhances neutrophil trogocytosis. Unlike CD47-targeting agents, ADU-1805 does not interfere with T-cell activation and is not expected to require frequent and extensive dosing due to the restricted expression of SIRPα to cells of the myeloid lineage. ADU-1805 is cross-reactive to cynomolgus monkey SIRPα and upon single-dose intravenous administration in these non-human primates (NHPs) did not show any signs of anemia, thrombocytopenia or other toxicities. <h3>Conclusions</h3> Blocking the SIRPα-CD47 interaction via SIRPα, while similarly efficacious in vitro, differentiates ADU-1805 from CD47-targeting agents with respect to safety and absence of inhibition of T-cell activation. The data presented herein support further advancement of ADU-1805 towards clinical development.
Abstract 17418: Platelet-Mediated Inflammation - Toll-Like Receptor 2 Stimulation Potently Induces Serotonin Release
Authors: Daniel Duerschmied, Pol Koch, Marie-Christine Alessi, Matthias Canault, Christoph Bode, Ingo Ahres
Journal: Circulation (2012)

Introduction A central role for the innate immunity-mediating toll-like receptors (TLRs) in atherosclerosis has recently emerged. Platelets are involved in early and late stages of atherosclerosis....
Prognostic factors for aggressive lymphoma patients treated with front-line autotransplantation after complete remission: A cohort study on 330 patients
Authors: N Mounier, C Gisselbrecht, J Briere, C Haioun, P Feugier, Fritz Offner, C Recher, A Stamatoullas, F Morschhauser, M Macro, C Thieblemont, A Bosly, B Fabiani, F Reyes
Journal: Blood (2003)
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
Authors: Jun-Hai Tang, Lin Yang, Ju-Xiang Chen, Qing-Rui Li, Li-Rong Zhu, Qing-Fu Xu, Guo-Hao Huang, Zuo-Xin Zhang, Yan Xiang, Lei Du, Zheng Zhou, Sheng-Qing Lv
Journal: Cancer Communications (2019)

High-grade glioma (HGG) is a fatal human cancer. Bortezomib, a proteasome inhibitor, has been approved for the treatment of multiple myeloma but its use in glioma awaits further investigation. This study aimed to explore the chemotherapeutic effect and the underlying mechanism of bortezomib on gliomas. U251 and U87 cell viability and proliferation were detected by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay, tumor cell spheroid growth, and colony formation assay. Cell apoptosis and cell cycle were detected by flow cytometry. Temozolomide (TMZ)-insensitive cell lines were induced by long-term TMZ treatment, and cells with stem cell characteristics were enriched with stem cell culture medium. The mRNA levels of interested genes were measured via reverse transcription-quantitative polymerase chain reaction, and protein levels were determined via Western blotting/immunofluorescent staining in cell lines and immunohistochemical staining in paraffin-embedded sections. Via inoculating U87 cells subcutaneously, glioma xenograft models in nude mice were established for drug experiments. Patient survival data were analyzed using the Kaplan–Meier method. Bortezomib inhibited the viability and proliferation of U251 and U87 cells in a dose- and time-dependent manner by inducing apoptosis and cell cycle arrest. Bortezomib also significantly inhibited the spheroid growth, colony formation, and stem-like cell proliferation of U251 and U87 cells. When administrated in combination, bortezomib showed synergistic effect with TMZ in vitro and sensitized glioma to TMZ treatment both in vitro and in vivo. Bortezomib reduced both the mRNA and protein levels of Forkhead Box M1 (FOXM1) and its target gene Survivin. The FOXM1–Survivin axis was markedly up-regulated in established TMZ-insensitive glioma cell lines and HGG patients. Expression levels of FOXM1 and Survivin were positively correlated with each other and both related to poor prognosis in glioma patients. Bortezomib was found to inhibit glioma growth and improved TMZ chemotherapy efficacy, probably via down-regulating the FOXM1–Survivin axis. Bortezomib might be a promising agent for treating malignant glioma, alone or in combination with TMZ.
雷尼酸锶治疗骨质疏松 治疗有效，但应慎重解释骨矿物质密度变化
Authors: Ignac, Fogelman, Glen, Blake, 张炬（译）, 董怡（校）
Journal: BMJ (2005)

有效治疗骨质疏松相对来说是近年来的事。这是在1996年阿仑膦酸试验。发表后才开始的，到现在双膦酸盐已经作为骨质疏松的一种明确的治疗选择了。目前主要的治疗措施是采用抗吸收药物来阻止骨破坏。有关该类药物的大多数研究均表明它们能很好地减少脊柱骨折，而作用更强的含氮双膦酸盐还显示可减少非脊柱骨折。对于曾有骨折的患者，选用促进骨形成的合成代谢药物无疑很有效，现在1-34重组甲状旁腺素（PTH）的应用也是一种可行的治疗方式。不过由于PTH价格昂贵，需要患者自己进行皮下注射，其使用受到一定的限制。最近雷尼酸锶在英国已经注册用于治疗骨质疏松。本文主要关注雷尼酸锶对骨矿物质密度的与众不同的作用，并讨论该作用对于评估治疗依从性的潜在益处。
Developing an Onboarding Framework for Surgeons in Expanding Health Systems
Authors: Jason C. Pradarelli, Janaka Lagoo, Susan Haas
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Long-Term Follow-up of 228 Hairy Cell Leukemia Patients Treated with Pentostatin or Cladribine with 15.4 Years Median Time from Diagnosis.
Authors: Monica Else, Claire E. Dearden, Estella Matutes, Ama Z S Rohatiner, Steve A N Johnson, Nigel T J O’Connor, Andy Haynes, Nnenna Osuji, Daniel Catovsky
Journal: Blood (2008)
Combining Measurements of Plasma Cell Apoptosis and Proliferation in Multiple Myeloma Identifies Patients with Poor Survival.
Authors: Shaji Kumar, Michael Timm, Martha Q. Lacy, Angela Dispenzieri, Suzanne R. Hayman, Morie A. Gertz, S. Vincent Rajkumar, Philip R. Greipp, Thomas E. Witzig
Journal: Blood (2005)
Retinoic Acid Blockade Increases Primitive Blood Cell Formation in cdx4 Mutant Zebrafish Embryos, Murine Yolk Sac Explants and Differentiated Embryonic Stem Cells.
Authors: Jill L. de Jong, Alan J. Davidson, Yuan Wang, James Palis, George Q. Daley, Leonard I. Zon
Journal: Blood (2007)
X-Ray Crystallographic and Single-Molecule Fluorescence Studies of Beta-2 Glycoprotein I Reveal an Alternative Mechanism of Autoantibody Recognition
Authors: William Planer, Zhiwei Chen, Mathivanan Chinnaraj, Xiaobing Zuo, Vittorio Pengo, Paolo Macor, Francesco Tedesco, Nicola Pozzi
Journal: Blood (2019)
Blood TfR+ exosomes separated by a pH-responsive method deliver chemotherapeutics for tumor therapy
Authors: Lijun Yang, Donglin Han, Qi Zhan, Xueping Li, Peipei Shan, Yunjie Hu, Han Ding, Yu Wang, Lei Zhang, Yuan Zhang, Sheng Xue, Jin Zhao, Xin Hou, Yin Wang, Peifeng Li, Xubo Yuan, Hongzhao Qi
Journal: Theranostics (2019)

Blood transferrin receptor-positive (TfR+) exosomes are a kind of optimized drug delivery vector compared with other kinds of exosomes due to their easy access and high bio-safety. Their application facilitates the translation from bench to bedside of exosome-based delivery vehicles. Methods: In this study, a pH-responsive superparamagnetic nanoparticles cluster (denoted as SMNC)-based method was developed for the precise and mild separation of blood TfR+ exosomes. Briefly, multiple superparamagnetic nanoparticles (SPMNs) labeled with transferrins (Tfs) could precisely bind to blood TfR+ exosomes to form an exosome-based cluster due to the specific recognition of TfR by Tf. They could realize the precise magnetic separation of blood TfR+ exosomes. More importantly, the pH-responsive dissociation characteristic of Tf and TfR led to the mild collapse of clusters to obtain pure blood TfR+ exosomes. Results: Blood TfR+ exosomes with high purity and in their original state were successfully obtained through the pH-responsive SMNC-based method. These can load Doxorubicin (DOX) with a loading capacity of ~10% and dramatically increase the tumor accumulation of DOX in tumor-bearing mice because of their innate passive-targeting ability. In addition, blood TfR+ exosomes changed the biodistribution of DOX leading to the reduction of side effects. Compared with free DOX, DOX-loaded blood TfR+ exosomes showed much better tumor inhibition effects on tumor-bearing mice. Conclusion: Taking advantage of the pH-responsive binding and disaggregation characteristics of Tf and TfR, the SMNC-based method can precisely separate blood TfR+ exosomes with high purity and in their original state. The resulting blood TfR+ exosomes showed excellent bio-safety and enable the efficient delivery of chemotherapeutics to tumors, facilitating the clinical translation of exosome-based drug delivery systems.
Inactivation of the Suv39h1 Histone Methyltransferase Accelerates Myc-Driven B-Cell Lymphomagenesis and Compromises Drug-Inducible Cellular Senescence.
Authors: Soyoung Lee, Vedrana Tabor, Christoph Loddenkemper, Antoine H.F.M. Peters, Harald Stein, Bernd Dorken, Thomas Jenuwein, Clemens A. Schmitt
Journal: Blood (2005)
The Determination of the Inhibitory Activity of Some Factor VIII Type II Inhibitor Antibodies Is Biased by the Type of Factor VIII Assay.
Authors: Marc G. Jacquemin, Seb Lamprecht, Renaud Lavend’homme, Jan Roodt, Bernard Chatelain, Veronique Deneys, Jeroen Dewaele, Jean-Marie Stassen, Muriel Meiring, Jean Marie Saint-Remy, Henry Pieters, Philip Badenhorst
Journal: Blood (2005)
The Effect of Paraprotein Heavy Chain and Free Light Chain Types on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Jatin Shah, Joan Blade, Pieter Sonneveld, Jesus San Miguel, Donghan Luo, Keith C Lantz, Colin Lowery, Jean-Luc Harousseau, Robert Z. Orlowski
Journal: Blood (2008)
关于“双胞胎自杀的危险性”一文的读者来信——自杀的社会因素
Authors: GeraldDSack
Journal: BMJ (2004)

由Tomassini等人撰写的文章(见本刊2003年第4期219页)分析了欧洲人的自杀问题，但未提及也未分析关于斯堪的纳维亚人自杀的情况^1-4。Tomassini的文章及人们对该文的反应均显示出了社会的无知。
Loss of histone macroH2A1 in hepatocellular carcinoma cells promotes paracrine-mediated chemoresistance and CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> regulatory T cells activation
Authors: Oriana Lo Re, Tommaso Mazza, Sebastiano Giallongo, Paola Sanna, Francesca Rappa, Tu Vinh Luong, Giovanni Li Volti, Adela Drovakova, Tania Roskams, Matthias Van Haele, Emmanuel Tsochatzis, Manlio Vinciguerra
Journal: Theranostics (2019)

Rationale: Loss of histone macroH2A1 induces appearance of cancer stem cells (CSCs)-like cells in hepatocellular carcinoma (HCC). How CSCs interact with the tumor microenvironment and the adaptive immune system is unclear. Methods: We screened aggressive human HCC for macroH2A1 and CD44 CSC marker expression. We also knocked down (KD) macroH2A1 in HCC cells, and performed integrated transcriptomic and secretomic analyses. Results: Human HCC showed low macroH2A1 and high CD44 expression compared to control tissues. MacroH2A1 KD CSC-like cells transferred paracrinally their chemoresistant properties to parental HCC cells. MacroH2A1 KD conditioned media transcriptionally reprogrammed parental HCC cells activated regulatory CD4+/CD25+/FoxP3+ T cells (Tregs). Conclusions: Loss of macroH2A1 in HCC cells drives cancer stem-cell propagation and evasion from immune surveillance.
BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Is a Novel, Potent Orally Active Anti-T-Cell and B-Cell Agent.
Authors: Shanta Bantia, Cynthia Parker, Ramanda Upshaw, John Michael Kilpatrick, Amanda Cunningham, Jianwen Zhang, Pravin Kotian, Philip Morris, Pooran Chand, Yarlagadda S. Babu
Journal: Blood (2008)
Afann: bias adjustment for alignment-free sequence comparison based on sequencing data using neural network regression
Authors: Kujin Tang, Jie Ren, Fengzhu Sun
Journal: Genome biology (2019)

Alignment-free methods, more time and memory efficient than alignment-based methods, have been widely used for comparing genome sequences or raw sequencing samples without assembly. However, in this study, we show that alignment-free dissimilarity calculated based on sequencing samples can be overestimated compared with the dissimilarity calculated based on their genomes, and this bias can significantly decrease the performance of the alignment-free analysis. Here, we introduce a new alignment-free tool, Alignment-Free methods Adjusted by Neural Network (Afann) that successfully adjusts this bias and achieves excellent performance on various independent datasets. Afann is freely available at https://github.com/GeniusTang/Afann.
Hematide™, a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), Demonstrates Erythropoietic Activity in a Phase 2 Single Dose, Dose Escalating Study in Patients with Chronic Kidney Disease (CKD).
Authors: Anne-Marie Duliege, Iain Macdougall, Neill Duncan, Dawie Wessels, Julie Iwashita, Pete Schatz, Robert Naso, Richard Stead, John Lambert
Journal: Blood (2005)